Carbon monoxide releasing molecule-2 improves coagulation in patient plasma in vitro following cardiopulmonary bypass

S. Nini Malayaman, John W C Entwistle, Percy Boateng, Andrew S. Wechsler, Joshua M. Persaud, Jack B. Cohen, James K. Kirklin, Vance G Nielsen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The objective of the present study was to determine if a new procoagulant molecule, carbon monoxide releasing molecule (tricarbonyldichlororuthenium (II) dimer; CORM-2) would improve coagulation following cardiopulmonary bypass (CPB). Plasma was obtained from patients undergoing elective cardiac surgery requiring CPB. Whole blood was collected and anticoagulated with sodium citrate after induction of anesthesia and again after CPB and heparin neutralization with protamine. Blood samples were centrifuged for 15 min, with plasma collected and stored at -80°C prior to analysis. Samples were subsequently exposed to 0 or 100 μmol/l CORM-2, with coagulation activated with tissue factor. Data were collected with thrombelastography until clot strength stabilized. Patients underwent CPB for 133± 61 min (mean ±SD). The velocity of thrombus formation was significantly decreased (52%) by CPB, as was clot strength (53%). Addition of CORM-2 to plasma samples obtained after CPB significantly increased the velocity of clot formation (75%) and strength (52%) compared to matched unexposed samples. The lesion of plasmatic coagulation associated with CPB was significantly improved in vitro by addition of CORM-2. If preclinical assessments of efficacy and safety of CORM-2 are favorable, future clinical trials involving CORM-2 or other CORMs as a hemostatic intervention in the setting of CPB are justified.

Original languageEnglish (US)
Pages (from-to)362-368
Number of pages7
JournalBlood Coagulation and Fibrinolysis
Volume22
Issue number5
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Carbon Monoxide
Cardiopulmonary Bypass
Thrombelastography
Protamines
In Vitro Techniques
Thromboplastin
Hemostatics
tricarbonyldichlororuthenium (II) dimer
Thoracic Surgery
Heparin
Thrombosis
Anesthesia
Clinical Trials
Safety

Keywords

  • carbon monoxide releasing molecule
  • cardiopulmonary bypass
  • coagulation
  • fibrinolysis
  • thrombelastography

ASJC Scopus subject areas

  • Hematology

Cite this

Carbon monoxide releasing molecule-2 improves coagulation in patient plasma in vitro following cardiopulmonary bypass. / Malayaman, S. Nini; Entwistle, John W C; Boateng, Percy; Wechsler, Andrew S.; Persaud, Joshua M.; Cohen, Jack B.; Kirklin, James K.; Nielsen, Vance G.

In: Blood Coagulation and Fibrinolysis, Vol. 22, No. 5, 07.2011, p. 362-368.

Research output: Contribution to journalArticle

Malayaman, S. Nini ; Entwistle, John W C ; Boateng, Percy ; Wechsler, Andrew S. ; Persaud, Joshua M. ; Cohen, Jack B. ; Kirklin, James K. ; Nielsen, Vance G. / Carbon monoxide releasing molecule-2 improves coagulation in patient plasma in vitro following cardiopulmonary bypass. In: Blood Coagulation and Fibrinolysis. 2011 ; Vol. 22, No. 5. pp. 362-368.
@article{58ce8aadc9b24eeb9ad509ea9601c38a,
title = "Carbon monoxide releasing molecule-2 improves coagulation in patient plasma in vitro following cardiopulmonary bypass",
abstract = "The objective of the present study was to determine if a new procoagulant molecule, carbon monoxide releasing molecule (tricarbonyldichlororuthenium (II) dimer; CORM-2) would improve coagulation following cardiopulmonary bypass (CPB). Plasma was obtained from patients undergoing elective cardiac surgery requiring CPB. Whole blood was collected and anticoagulated with sodium citrate after induction of anesthesia and again after CPB and heparin neutralization with protamine. Blood samples were centrifuged for 15 min, with plasma collected and stored at -80°C prior to analysis. Samples were subsequently exposed to 0 or 100 μmol/l CORM-2, with coagulation activated with tissue factor. Data were collected with thrombelastography until clot strength stabilized. Patients underwent CPB for 133± 61 min (mean ±SD). The velocity of thrombus formation was significantly decreased (52{\%}) by CPB, as was clot strength (53{\%}). Addition of CORM-2 to plasma samples obtained after CPB significantly increased the velocity of clot formation (75{\%}) and strength (52{\%}) compared to matched unexposed samples. The lesion of plasmatic coagulation associated with CPB was significantly improved in vitro by addition of CORM-2. If preclinical assessments of efficacy and safety of CORM-2 are favorable, future clinical trials involving CORM-2 or other CORMs as a hemostatic intervention in the setting of CPB are justified.",
keywords = "carbon monoxide releasing molecule, cardiopulmonary bypass, coagulation, fibrinolysis, thrombelastography",
author = "Malayaman, {S. Nini} and Entwistle, {John W C} and Percy Boateng and Wechsler, {Andrew S.} and Persaud, {Joshua M.} and Cohen, {Jack B.} and Kirklin, {James K.} and Nielsen, {Vance G}",
year = "2011",
month = "7",
doi = "10.1097/MBC.0b013e328344c66c",
language = "English (US)",
volume = "22",
pages = "362--368",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Carbon monoxide releasing molecule-2 improves coagulation in patient plasma in vitro following cardiopulmonary bypass

AU - Malayaman, S. Nini

AU - Entwistle, John W C

AU - Boateng, Percy

AU - Wechsler, Andrew S.

AU - Persaud, Joshua M.

AU - Cohen, Jack B.

AU - Kirklin, James K.

AU - Nielsen, Vance G

PY - 2011/7

Y1 - 2011/7

N2 - The objective of the present study was to determine if a new procoagulant molecule, carbon monoxide releasing molecule (tricarbonyldichlororuthenium (II) dimer; CORM-2) would improve coagulation following cardiopulmonary bypass (CPB). Plasma was obtained from patients undergoing elective cardiac surgery requiring CPB. Whole blood was collected and anticoagulated with sodium citrate after induction of anesthesia and again after CPB and heparin neutralization with protamine. Blood samples were centrifuged for 15 min, with plasma collected and stored at -80°C prior to analysis. Samples were subsequently exposed to 0 or 100 μmol/l CORM-2, with coagulation activated with tissue factor. Data were collected with thrombelastography until clot strength stabilized. Patients underwent CPB for 133± 61 min (mean ±SD). The velocity of thrombus formation was significantly decreased (52%) by CPB, as was clot strength (53%). Addition of CORM-2 to plasma samples obtained after CPB significantly increased the velocity of clot formation (75%) and strength (52%) compared to matched unexposed samples. The lesion of plasmatic coagulation associated with CPB was significantly improved in vitro by addition of CORM-2. If preclinical assessments of efficacy and safety of CORM-2 are favorable, future clinical trials involving CORM-2 or other CORMs as a hemostatic intervention in the setting of CPB are justified.

AB - The objective of the present study was to determine if a new procoagulant molecule, carbon monoxide releasing molecule (tricarbonyldichlororuthenium (II) dimer; CORM-2) would improve coagulation following cardiopulmonary bypass (CPB). Plasma was obtained from patients undergoing elective cardiac surgery requiring CPB. Whole blood was collected and anticoagulated with sodium citrate after induction of anesthesia and again after CPB and heparin neutralization with protamine. Blood samples were centrifuged for 15 min, with plasma collected and stored at -80°C prior to analysis. Samples were subsequently exposed to 0 or 100 μmol/l CORM-2, with coagulation activated with tissue factor. Data were collected with thrombelastography until clot strength stabilized. Patients underwent CPB for 133± 61 min (mean ±SD). The velocity of thrombus formation was significantly decreased (52%) by CPB, as was clot strength (53%). Addition of CORM-2 to plasma samples obtained after CPB significantly increased the velocity of clot formation (75%) and strength (52%) compared to matched unexposed samples. The lesion of plasmatic coagulation associated with CPB was significantly improved in vitro by addition of CORM-2. If preclinical assessments of efficacy and safety of CORM-2 are favorable, future clinical trials involving CORM-2 or other CORMs as a hemostatic intervention in the setting of CPB are justified.

KW - carbon monoxide releasing molecule

KW - cardiopulmonary bypass

KW - coagulation

KW - fibrinolysis

KW - thrombelastography

UR - http://www.scopus.com/inward/record.url?scp=79960699795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960699795&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e328344c66c

DO - 10.1097/MBC.0b013e328344c66c

M3 - Article

C2 - 21346555

AN - SCOPUS:79960699795

VL - 22

SP - 362

EP - 368

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 5

ER -